Chimerix (CMRX) was a prime acquisition candidate for Jazz Pharmaceuticals (JAZZ) due to dordaviprone's unique positioning and likely near-term approval to treat H3-K27M mutant glioma, Wedbush said in a note Wednesday.
Jazz said Wednesday it agreed to acquire Chimerix for $8.55 per share in an all-cash deal, about a 72% premium over its previous closing price and in-line with the estimated fair value of dordaviprone, the investment firm said.
There does not appear to be any antitrust issues because Jazz does not have a presence glioma, Wedbush said.
Wedbush downgraded Chimerix to neutral from outperform and raised its price target to $8.55, reflecting the cash tender offer.
Shares of Chimerix were up almost 69% in recent trading.
Price: 8.43, Change: +3.47, Percent Change: +69.96
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.